title: Prospective study of predictors of vitamin D status and survival in patients with colorectal cancer.
abstract: BACKGROUND
  In an earlier study, a 25-hydroxyvitamin D(3) (25(OH)D) score calculated from known predictors of vitamin D status significantly predicted plasma levels of 25(OH)D and the risk of colorectal cancer, but the influence of the 25(OH)D score on survival after diagnosis is unknown.
  
  
  METHODS
  We prospectively examined the influence of post-diagnosis predicted 25(OH)D levels on mortality among 1017 participants in the Nurses' Health Study and Health Professionals Follow-Up Study who were diagnosed with colorectal cancer from 1986 to 2004. Colorectal cancer-specific and overall mortality according to quintiles of predicted 25(OH)D levels were assessed. Cox proportional hazards models were used to calculate hazard ratios (HRs) adjusted for other risk factors of survival.
  
  
  RESULTS
  Higher predicted 25(OH)D levels were associated with a significant reduction in colorectal cancer-specific (P trend=0.02) and overall mortality (P trend=0.002). Compared with levels in the lowest quintile, participants with predicted 25(OH)D levels in the highest quintile had an adjusted HR of 0.50 (95% CI, 0.26-0.95) for cancer-specific mortality and 0.62 (95% CI, 0.42-0.93) for overall mortality.
  
  
  CONCLUSIONS
  Higher predicted 25(OH)D levels after a diagnosis of colorectal cancer may be associated with improved survival. Further study of the vitamin D pathway in colorectal cancer is warranted.
authors.affiliation: Department of Medical Oncology, Dana-Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA. Kimmie_Ng@dfci.harvard.edu
authors.forename: K
authors.initials: K
authors.lastname: Ng
authors.forename: B M
authors.initials: BM
authors.lastname: Wolpin
authors.forename: J A
authors.initials: JA
authors.lastname: Meyerhardt
authors.forename: K
authors.initials: K
authors.lastname: Wu
authors.forename: A T
authors.initials: AT
authors.lastname: Chan
authors.forename: B W
authors.initials: BW
authors.lastname: Hollis
authors.forename: E L
authors.initials: EL
authors.lastname: Giovannucci
authors.forename: M J
authors.initials: MJ
authors.lastname: Stampfer
authors.forename: W C
authors.initials: WC
authors.lastname: Willett
authors.forename: C S
authors.initials: CS
authors.lastname: Fuchs
mesh_terms: D000328:Adult; D000368:Aged; D015992:Body Mass Index; D015179:Colorectal Neoplasms / Q000097:blood* / Q000401:mortality*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D014807:Vitamin D / Q000031:analogs & derivatives* / Q000097:blood
chemical_list: D014807:Vitamin D; C104450:25-hydroxyvitamin D
references.citation: J Clin Oncol. 2006 Aug 1;24(22):3535-41
references.pmid: 16822843
references.citation: Cancer Lett. 1994 Oct 28;86(1):67-73
references.pmid: 7954357
references.citation: Int J Cancer. 1999 May 31;81(5):730-3
references.pmid: 10328225
references.citation: Cancer Res. 2000 Apr 15;60(8):2304-12
references.pmid: 10786699
references.citation: Nat Rev Cancer. 2007 Sep;7(9):684-700
references.pmid: 17721433
references.citation: Am J Epidemiol. 1984 May;119(5):837-9
references.pmid: 6720679
references.citation: Cancer Causes Control. 1997 Jul;8(4):615-25
references.pmid: 9242478
references.citation: Endocrinology. 1993 Apr;132(4):1808-14
references.pmid: 8384998
references.citation: Cancer Res. 1987 Jan 1;47(1):21-5
references.pmid: 3024816
references.citation: J Womens Health. 1997 Feb;6(1):49-62
references.pmid: 9065374
references.citation: Endocrinology. 2000 Nov;141(11):3931-9
references.pmid: 11089522
references.citation: J Clin Oncol. 2008 Sep 1;26(25):4109-15
references.pmid: 18757324
references.citation: N Engl J Med. 1982 Mar 25;306(12):722-5
references.pmid: 7038486
references.citation: Eur J Clin Nutr. 2003 Jan;57(1):1-17
references.pmid: 12548291
references.citation: Ann N Y Acad Sci. 2001 Dec;952:73-87
references.pmid: 11795445
references.citation: Am J Prev Med. 2007 Mar;32(3):210-6
references.pmid: 17296473
references.citation: J Clin Oncol. 2008 Jun 20;26(18):2984-91
references.pmid: 18565885
references.citation: Am J Epidemiol. 1995 Sep 15;142(6):608-11
references.pmid: 7653469
references.citation: Methods Enzymol. 1997;282:174-86
references.pmid: 9330287
references.citation: Cancer Causes Control. 2003 Feb;14(1):1-12
references.pmid: 12708719
references.citation: Int J Oncol. 2000 Jun;16(6):1249-54
references.pmid: 10812003
references.citation: J Natl Cancer Inst. 2007 Jul 18;99(14):1120-9
references.pmid: 17623801
references.citation: N Engl J Med. 2006 Feb 16;354(7):684-96
references.pmid: 16481636
references.citation: Cancer. 2002 Jul 1;95(1):39-46
references.pmid: 12115315
references.citation: J Natl Cancer Inst. 2006 Apr 5;98(7):451-9
references.pmid: 16595781
references.citation: J Clin Oncol. 2006 Aug 1;24(22):3527-34
references.pmid: 16822844
references.citation: Am J Clin Nutr. 2007 Jun;85(6):1586-91
references.pmid: 17556697
references.citation: Am J Nurs. 1978 Jun;78(6):1039-40
references.pmid: 248266
references.citation: Cancer Res. 1991 Feb 15;51(4):1227-33
references.pmid: 1847660
references.citation: Cancer Epidemiol Biomarkers Prev. 2004 Sep;13(9):1502-8
references.pmid: 15342452
references.citation: Cancer Lett. 1995 Oct 20;97(1):99-106
references.pmid: 7585485
references.citation: Oncogene. 2005 Sep 29;24(43):6533-44
references.pmid: 16007183
references.citation: J Clin Endocrinol Metab. 2001 Feb;86(2):888-94
references.pmid: 11158062
references.citation: Arch Biochem Biophys. 1991 Mar;285(2):261-9
references.pmid: 1654769
references.citation: Lancet. 1989 Nov 18;2(8673):1176-8
references.pmid: 2572900
references.citation: J Natl Cancer Inst. 1994 Feb 2;86(3):192-9
references.pmid: 8283491
references.citation: Cancer Res. 1994 Aug 1;54(15):4057-64
references.pmid: 8033137
references.citation: J Natl Cancer Inst. 2002 Mar 20;94(6):437-46
references.pmid: 11904316
references.citation: J Occup Environ Med. 1998 Sep;40(9):808-13
references.pmid: 9777565